This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ochsner, U. A. Articles by Critchley, I. A. Search for Related Content PubMed PubMed Citation Articles by Ochsner, U. A. Articles by Critchley, I. A.

Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase

Replidyne, Inc., Louisville, Colorado 80027

Received 19 May 2005/ Returned for modification 14 July 2005/ Accepted 26 July 2005

Aminoacyl-tRNA synthetases have attracted interest as essential and novel targets involved in bacterial protein synthesis. REP8839 is a potent inhibitor of MetS, the methionyl-tRNA synthetase in Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), and in Streptococcus pyogenes. The biochemical activity of REP8839 was shown by specific inhibition of purified S. aureus MetS (50% inhibitory concentration, <1.9 nM). Target specificity was confirmed by overexpression of the metS gene in S. aureus, resulting in an eightfold increase in the MIC for REP8839. Macromolecular synthesis assays in the presence of REP8839 demonstrated a dose-dependent inhibition of protein synthesis and RNA synthesis in S. pneumoniae R6, but only protein synthesis was affected in an isogenic rel mutant deficient in the stringent response. Strains with reduced susceptibility to REP8839 were generated by selection of strains with spontaneous mutations and through serial passages. Point mutations within the metS gene were mapped, leading to a total of 23 different amino acid substitutions within MetS that were located around the modeled active site. The most frequent MetS mutations were I57N, leading to a shift in the MIC from 0.06 µg/ml to 4 µg/ml, and G54S, resulting in a MIC of 32 µg/ml that was associated with a reduced growth rate. The mutation prevention concentration was 32 µg/ml in four S. aureus strains (methicillin-sensitive S. aureus and MRSA), which is well below the drug concentration of 2% (20,000 µg/ml) in a topical formulation. In conclusion, we demonstrate by biochemical, physiologic, and genetic mode-of-action studies that REP8839 exerts its antibacterial activity through specific inhibition of MetS, a novel target.

This article has been cited by other articles:

• Wu, Y., Yu, K., Xu, B., Chen, L., Chen, X., Mao, J., Danchin, A., Shen, X., Qu, D., Jiang, H. (2007). Potent and selective inhibitors of Staphylococcus epidermidis tryptophanyl-tRNA synthetase. J Antimicrob Chemother 60: 502-509 [Abstract] [Full Text]  
• Kedar, G. C., Brown-Driver, V., Reyes, D. R., Hilgers, M. T., Stidham, M. A., Shaw, K. J., Finn, J., Haselbeck, R. J. (2007). Evaluation of the metS and murB Loci for Antibiotic Discovery Using Targeted Antisense RNA Expression Analysis in Bacillus anthracis. Antimicrob. Agents Chemother. 51: 1708-1718 [Abstract] [Full Text]  
• Critchley, I. A., Young, C. L., Stone, K. C., Ochsner, U. A., Guiles, J., Tarasow, T., Janjic, N. (2005). Antibacterial Activity of REP8839, a New Antibiotic for Topical Use. Antimicrob. Agents Chemother. 49: 4247-4252 [Abstract] [Full Text]